Bollywood actor-turned-politician Kirron Kher, who had been diagnosed with multiple myeloma – a type of blood cancer – earlier this year is on the road to recovery, her husband and veteran star Anupam Kher confirmed in a statement. The Kuch Kuch Hota Hai actor, who updates his fans regularly about his wife's health recently told the Times of India that she is doing better but some days are more difficult than others.
“Kirron's health is improving. It's a tough treatment. She often says that the lockdown and COVID situation have made things difficult. Patients going through this treatment need something to distract themselves. She can't go out or meet people, but the good part is that Kirron is on her way to better health,” he said.
Anupam added, “She is holding up fine. There are days when she is positive and then there are days when the chemotherapy impacts her state in many ways. We are all trying our best and she is doing it, too.” The actor also shared that Hollywood actor Robert De Niro, who he is friends with, regularly messages to ask about Kirron's health. “Robert had messaged me when he learned about Kirron's health. He had also sent me a video to wish me on my birthday, and he keeps checking on Kirron's health every few days. I had texted him after seeing his ad with Roger Federer, and in response, all he wanted to know was my family's well-being and how Kirron was doing,” Anupam noted.
He confirmed the news of his wife's illness on Twitter in April. The actor wrote, “Just so that the rumours don't get the better of a situation, Sikandar (their son) and I would like to inform everyone that my wife has been diagnosed with multiple myeloma, a type of blood cancer. She is currently undergoing treatment and I am sure that she will come out of this stronger than before." Kher added that she is being looked after by a "phenomenal" set of doctors.
Have something to add to the story? Share it in the comments below.
Comments are moderated and generally will be posted if they are on-topic and not abusive.
For more information, please see our Comments FAQ